Interventions for preventing weight gain after smoking cessation (Q24241751)

Europe PubMed Central

title

Interventions for preventing weight gain after smoking cessation (English)

0 references

1 reference

1 reference

Paul Aveyard

4

0 references

Mujahed Shraim

object named as

Mujahed Shraim

2

0 references

Amanda Parsons

1

object named as

Amanda C Parsons

0 references

author name string

Jennie Inglis

3

0 references

Peter Hajek

Cochrane Database of Systematic Reviews

5

0 references

publication date

21 January 2009

0 references

published in

0 references

cites work

A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Smoking cessation for weight-concerned women: group vs. individually tailored, dietary, and weight-control follow-up sessions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Open randomised trial of intermittent very low energy diet together with nicotine gum for stopping smoking in women who gained weight in previous attempts to quit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The effects of phenylpropanolamine on dietary intake, physical activity, and body weight after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effects of phenylpropanolamine on withdrawal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

21 January 2018

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Bupropion for smoking cessation : predictors of successful outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Elevated positive mood: a mixed blessing for abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Bupropion for smokers hospitalized with acute cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The "bupropion for smoking cessation" trial from a family practice perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Bupropion for smoking cessation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The efficacy of moderate-intensity exercise as an aid for smoking cessation in women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Efficacy of exercise counselling as an aid for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Randomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Gender differences in quit rates following smoking cessation with combination nicotine therapy: Influence of baseline smoking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

High-dose nicotine patch therapy. Percentage of replacement and smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Weight change after smoking cessation using variable doses of transdermal nicotine replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Predicting smoking cessation. Who will quit with and without the nicotine patch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effects of nicotine gum dose by level of nicotine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Long-term effects of nicotine gum on weight gain after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Dose effects of nicotine gum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Nicotine lozenge efficacy in light smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Use of more nicotine lozenges leads to better success in quitting smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Efficacy of a nicotine lozenge for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

How much does relapse after one year erode effectiveness of smoking cessation treatments? Long-term follow up of randomised trial of nicotine nasal spray

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Randomised controlled trial of nasal nicotine spray in smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Weight change among participants in a large sample minimal contact smoking relapse prevention trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effects of biochemically confirmed smoking cessation on white blood cell count

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The effect of bupropion sustained-release on cigarette craving after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Effects of gender on relapse prevention in smokers treated with bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A comparison of a nicotine sublingual tablet and placebo for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

A double blind study of 2 mg versus 4 mg nicotine-gum in an industrial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Exercise as an adjunct to nicotine gum in treating tobacco dependence among women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The effects of exercise and nicotine replacement therapy on smoking rates in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Rimonabant--a selective CB1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Smoking cessation, lung function, and weight gain: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Weight concerns among male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Smoking cessation and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Antidepressants for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Early and late weight gain following smoking cessation in the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Nicotine replacement therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Exercise interventions for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Smoking as a weight-control strategy and its relationship to smoking status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Glucose for smoking cessation: does it have a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

Smoking cessation and severity of weight gain in a national cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

The nicotine inhaler in smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

The use of transdermal nicotine in smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Controlled trial of transdermal nicotine patch in tobacco withdrawal

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Nicotine replacement: effects of postcessation weight gain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Weight suppression and weight rebound in ex-smokers treated with fluoxetine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Influences of gender and weight gain on short-term relapse to smoking in a cessation trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Factors associated with participation, attrition, and outcome in a smoking cessation program at the workplace

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Correspondence programs for smoking cessation and weight control: a comparison of two strategies in the Minnesota Heart Health Program.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Do heavy smokers benefit from higher dose nicotine patch therapy?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

A comparison of sustained-release bupropion and placebo for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Weight gain prevention and smoking cessation: cautionary findings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Smoking cessation in women concerned about weight

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021

Bupropion SR vs placebo for smoking cessation in health care professionals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006219.PUB2

7 January 2021